azilsartan medoxomil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic)	4322	863031-21-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

TAK 491
edarbi
azilsartan medoxomil
azilsartan kamedoxomil

an angiotensin type 1 receptor blocker; receptor blocker

Molecular weight: 568.54
Formula: C30H24N4O8
CLOGP: 4.24
LIPINSKI: 2
HAC: 12
HDO: 1
TPSA: 139.57
ALOGS: -4.91
ROTB: 10

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 2011	FDA	ARBOR PHARMS IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	49.38	21.52	33	1850	74339	46609840
Hepatic function abnormal	43.08	21.52	23	1860	34398	46649781
Cerebral infarction	42.14	21.52	20	1863	23346	46660833
Platelet count decreased	32.40	21.52	29	1854	99995	46584184
Hyperkalaemia	30.05	21.52	21	1862	50688	46633491
Hypertension	28.18	21.52	37	1846	196319	46487860
Decreased appetite	25.48	21.52	35	1848	193801	46490378
Product odour abnormal	23.30	21.52	6	1877	1130	46683049

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	90.35	20.94	43	2281	26330	29923824
Hepatic function abnormal	69	20.94	42	2282	41903	29908251
Renal impairment	60.77	20.94	51	2273	84133	29866021
Fibrillary glomerulonephritis	53.23	20.94	8	2316	41	29950113
Interstitial lung disease	46.57	20.94	38	2286	60159	29889995
Proteinuria	31.29	20.94	18	2306	16127	29934027
Nephrotic syndrome	29.06	20.94	13	2311	6872	29943282
Thrombotic cerebral infarction	27.25	20.94	6	2318	299	29949855
Altered state of consciousness	25.36	20.94	17	2307	19902	29930252
Hepatocellular carcinoma	24.94	20.94	13	2311	9597	29940557
Hyperuricaemia	22.09	20.94	11	2313	7383	29942771
Haemorrhagic cerebral infarction	21.60	20.94	6	2318	780	29949374
Decreased appetite	21.21	20.94	40	2284	149870	29800284

Pharmacologic Action:

Source	Code	Description
ATC	C09CA09	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA09	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
MeSH PA	D047228	Angiotensin II Type 1 Receptor Blockers
MeSH PA	D057911	Angiotensin Receptor Antagonists
FDA MoA	N0000180999	Angiotensin 2 Type 1 Receptor Antagonists
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker
FDA PE	N0000178477	Decreased Blood Pressure
CHEBI has role	CHEBI:35674	antihypertensive
CHEBI has role	CHEBI:50266	prodrugs
CHEBI has role	CHEBI:61016	angiotensin receptor antagonists

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Hypovolemia	contraindication	28560003
Low blood pressure	contraindication	45007003
Hyponatremia	contraindication	89627008
Impaired renal function disorder	contraindication	197663003
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.11	acidic
pKa2	3.02	Basic
pKa3	2.4	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST				UNKNOWN	CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	6.38		CHEMBL

External reference:

ID	Source
WEC6I2K1FC	UNII
D08067	KEGG_DRUG
863031-24-7	SECONDARY_CAS_RN
147403-03-0	SECONDARY_CAS_RN
4030593	VANDF
4030594	VANDF
C2698290	UMLSCUI
C1958569	UMLSCUI
CHEBI:68845	CHEBI
CHEBI:68850	CHEBI
CHEMBL2103795	ChEMBL_ID
CHEMBL2028661	ChEMBL_ID
DB08822	DRUGBANK_ID
CHEMBL57242	ChEMBL_ID
23699544	PUBCHEM_CID
8874	INN_ID
C557413	MESH_SUPPLEMENTAL_RECORD_UI
6900	IUPHAR_LIGAND_ID
C521273	MESH_SUPPLEMENTAL_RECORD_UI
8724	INN_ID
F9NUX55P23	UNII
135415867	PUBCHEM_CID
6901	IUPHAR_LIGAND_ID
1091642	RXNORM
180314	MMSL
27787	MMSL
d07754	MMSL
013661	NDDF
013662	NDDF
448917007	SNOMEDCT_US
449042005	SNOMEDCT_US
449561004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Edarbi	HUMAN PRESCRIPTION DRUG LABEL	1	60631-040	TABLET	40 mg	ORAL	NDA	32 sections
Edarbi	HUMAN PRESCRIPTION DRUG LABEL	1	60631-080	TABLET	80 mg	ORAL	NDA	32 sections
Edarbyclor	HUMAN PRESCRIPTION DRUG LABEL	2	60631-412	TABLET	40 mg	ORAL	NDA	32 sections
Edarbyclor	HUMAN PRESCRIPTION DRUG LABEL	2	60631-425	TABLET	40 mg	ORAL	NDA	32 sections